Antiepileptic drug therapy: does mechanism of action matter? (Q37901704)

25 August 2017

1 reference

title

Antiepileptic drug therapy: does mechanism of action matter? (English)

1 reference

25 August 2017

1

Martin J Brodie

1 reference

25 August 2017

6

Graeme J Sills

1 reference

25 August 2017

5

Emilio Perucca

1 reference

25 August 2017

Athanasios Covanis

2

1 reference

25 August 2017

Antonio Gil-Nagel

series ordinal

3

1 reference

25 August 2017

Holger Lerche

series ordinal

4

1 reference

25 August 2017

H Steve White

series ordinal

7

1 reference

25 August 2017

publication date

16 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

21

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

331-341

1 reference

Update on anticonvulsant drugs

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Likelihood of seizure remission in an adult population with refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Results of treatment changes in patients with apparently drug-resistant chronic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Status epilepticus in children with newly diagnosed epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch Study of Epilepsy in Childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Polytherapy in the preventive and acute treatment of migraine: fundamentals for changing the approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Improving blood pressure control rates by optimizing combination antihypertensive therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Sodium channel mutations in epilepsy and other neurological disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

NaV1.1 channels and epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Localization and targeting of voltage-dependent ion channels in mammalian central neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

inferred from DOI database lookup

7 January 2021

based on heuristic

Calcium-sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Acquired dendritic channelopathy in temporal lobe epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Antiepileptic drugs--calcium current interaction in cultured human neuroblastoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The mechanisms of action of commonly used antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Pharmacotherapy of epilepsy: newly approved and developmental agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Pathways modulating neural KCNQ/M (Kv7) potassium channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The neurobiology of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Key factors in the discovery and development of new antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Development of new pharmacological agents for epilepsy: lessons from the kindling model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Antiepileptic drugs as a cause of worsening seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Discovery of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Commentary: novel delivery approaches for antiepileptic drugs: hope and hurdles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Randomized trial of vigabatrin in patients with infantile spasms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Adverse effects of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lamotrigine monotherapy for newly diagnosed typical absence seizures in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Safety of zonisamide therapy: prospective follow-up survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Erratum to "Safety of zonisamide therapy: prospective follow-up survey.".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Vigabatrin and behaviour disturbances.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Seizures and antiepileptic drugs: does exposure alter normal brain development?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

On the origin of interictal activity in human temporal lobe epilepsy in vitro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Sodium valproate: monotherapy and polytherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Valproic acid monotherapy in pregnancy and major congenital malformations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Teratogenic effects of antiepileptic medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Early cognitive development in children born to women with epilepsy: a prospective report.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Use of second-generation antiepileptic drugs in the pediatric population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Levetiracetam monotherapy in juvenile myoclonic epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Absence epilepsy: early prognostic signs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Valproate-ethosuximide combination therapy for refractory absence seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Aggravation of epilepsy by antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lamotrigine-associated rash: risk/benefit considerations in adults and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Combination therapy in epilepsy: when and what to use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Landau-Kleffner Syndrome: A Pharmacologic Study of Five Cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Status epilepticus of benign partial epilepsies in children: report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The influence of sulthiame on EEG in children with benign childhood epilepsy with centrotemporal spikes (BECTS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Treatment with Sulthiame (Ospolot) in benign partial epilepsy of childhood and related syndromes: an open clinical and EEG study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Report of the ILAE classification core group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Vigabatrin as a first-line drug in West syndrome: clinical and electroencephalographic outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Sodium channel SCN1A and epilepsy: mutations and mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Efficacy and safety of topiramate in refractory epilepsy of childhood: long-term follow-up study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Sulthiame therapy for continuous spike and wave in slow-wave sleep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

An overview of drug combination analysis with isobolograms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Antiepileptic drug combinations and experimental background: the case of phenobarbital and phenytoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Phenytoin and carbamazepine, alone and in combination: anticonvulsant and neurotoxic effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Mechanisms of action of antiepileptic drugs: the search for synergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Polytherapy in epilepsy: the experimental evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Synergistic interaction between valproate and lamotrigine against seizures induced by 4-aminopyridine and pentylenetetrazole in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Effect of gabapentin on the anticonvulsant activity of antiepileptic drugs against electroconvulsions in mice: an isobolographic analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Valproic acid in epilepsy: Clinical and pharmacological effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Clinically relevant drug interactions with antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Safety review of adult clinical trial experience with lamotrigine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Epilepsy after the first drug fails: substitution or add-on?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The efficacy of carbamazepine combinations in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Synergism with GABAergic drugs in refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lamotrigine and topiramate may be a useful combination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Definition of refractory epilepsy: defining the indefinable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Seizure freedom with more than one antiepileptic drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Staged approach to epilepsy management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Pharmacological management of epilepsy: recent advances and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Reappraisal of polytherapy in epilepsy: a critical review of drug load and adverse effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Patients with refractory seizures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Models for epilepsy and epileptogenesis: report from the NIH workshop, Bethesda, Maryland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

A novel mechanism underlying drug resistance in chronic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

GABA(A) receptor channel pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Selective changes in single cell GABA(A) receptor subunit expression and function in temporal lobe epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Voltage-gated potassium channels as therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Potassium channels: brief overview and implications in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Molecular targets for antiepileptic drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Neocortical seizures: initiation, development and cessation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Gap junctions and neurological disorders of the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Connexin expression in electrically coupled postnatal rat brain neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Antiabsence effects of carbenoxolone in two genetic animal models of absence epilepsy (WAG/Rij rats and lh/lh mice).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Antiepileptic effect of gap-junction blockers in a rat model of refractory focal cortical epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Pathophysiology of HCN channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Absence epilepsy and sinus dysrhythmia in mice lacking the pacemaker channel HCN2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Seizure-induced plasticity of h channels in entorhinal cortical layer III pyramidal neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Pharmacological characterization of antiepileptic drugs and experimental analgesics on low magnesium-induced hyperexcitability in rat hippocampal slices

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

Disease modification in partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2011.05.025

10.1016/J.YEBEH.2011.05.025

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference